← Leaderboards
Brian K Kaspar
Research Inst Nationwide Children'S Hosp
$5,992,068
Attributed
$6,371,705
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–15$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$6,371,705 · 7
By mechanism
U01$2,614,318 · 1
R21$2,215,240 · 5
R01$1,542,147 · 1
Top collaborators
- Arthur H.M Burghes2 shared
Most similar at Research Inst Nationwide Children'S Hosp
Same institution · by research overlap
- Catherine Dominguez$142,412
- Jordan Tanin Gladman$96,022
- Bruce A Bunnell$8,257,071
- Kathrin Meyer$2,136,536
- Lindsay N Alfano$752,794
Others in their field
Top investigators on “Motor Neurons”
- Merit E Cudkowicz · Massachusetts General Hospital$50,666,157
- Jerrold L Vitek · University Of Minnesota$28,920,065
- Daniel M Corcos · Northwestern University$27,398,302
- Richard A Andersen · California Institute Of Technology$25,841,240
- Martyn D Goulding · Salk Institute For Biological Studies$22,530,165
- Peter L Strick · University Of Minnesota Twin Cities$20,725,006
Research focus
Motor NeuronsMouse ModelGene TherapyVectorSpinal CordCessation Of LifeLongevityGene DeliveryDependovirusMutationMuscleAnimalsMotorReportingClinical TrialsCellsBaseMotor Neuron DiseaseLaboratoriesAmyotrophic Lateral SclerosisRespiratory FailureOnset Of IllnessParalysedAffect
Grant awards (17)
Creation and correction of Spinal Muscular Atrophy in the pig$379,750
R21 · FY2015 · NS
Translating a CSF delivered AAV9-SMN for treatment of Spinal Muscular Atrophy$1,155,044
U01 · FY2014 · NS · contact PI
Creation and correction of Spinal Muscular Atrophy in the pig$379,525
R21 · FY2014 · NS
Translating a CSF delivered AAV9-SMN for treatment of Spinal Muscular Atrophy$1,459,274
U01 · FY2013 · NS · contact PI
Role of Potent Trophic Factors on Glia and Motor Neurons in ALS$297,896
R01 · FY2013 · NS · contact PI
Defining a clinically relevant time point for astrocyte targeted therapy in ALS$210,611
R21 · FY2013 · NS · contact PI
Role of Potent Trophic Factors on Glia and Motor Neurons in ALS$308,700
R01 · FY2012 · NS · contact PI
Defining a clinically relevant time point for astrocyte targeted therapy in ALS$181,875
R21 · FY2012 · NS · contact PI
Role of Potent Trophic Factors on Glia and Motor Neurons in ALS$308,700
R01 · FY2011 · NS · contact PI
Role of Potent Trophic Factors on Glia and Motor Neurons in ALS$311,851
R01 · FY2010 · NS · contact PI
Role of Potent Trophic Factors on Glia and Motor Neurons in ALS$315,000
R01 · FY2009 · NS · contact PI
Novel Gene Delivery Development for Spinal Muscular Atrophy$189,000
R21 · FY2009 · NS · contact PI
Gene Delivery to the CNS through the Deep Cerebellar Nucleus$176,400
R21 · FY2008 · EY · contact PI
Novel Gene Delivery Development for Spinal Muscular Atrophy$157,500
R21 · FY2008 · NS · contact PI
Gene Delivery to the CNS through the Deep Cerebellar Nucleus$216,000
R21 · FY2007 · EY · contact PI
Engineering AAV for Enhanced Retrograde Transport$165,405
R21 · FY2006 · NS · contact PI
Engineering AAV for Enhanced Retrograde Transport$159,174
R21 · FY2005 · NS